Exelixis’ cabozantinib gets FDA breakthrough therapy status for renal cell carcinoma

Biopharmaceutical firm Exelixis has received breakthrough therapy designation from the US Food & Drug Administration (FDA) for its cabozantinib to treat patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news